<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196244</url>
  </required_header>
  <id_info>
    <org_study_id>INCARO-HYKS</org_study_id>
    <nct_id>NCT04196244</nct_id>
  </id_info>
  <brief_title>Intravenous Contrast Computed Tomography Versus Native Computed Tomography in Patients With Acute Abdomen and Impaired Renal Function</brief_title>
  <acronym>INCARO</acronym>
  <official_title>INtravenous Contrast Computed Tomography Versus Native Computed Tomography in Patients With Acute Abdomen and Impaired Renal functiOn (INCARO) - a Multicentre, Open-label, Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Computer tomography (CT) is the primary imaging option for acute abdominal pain in adults.
      Intravenous (IV) contrast media is used to improve the CT quality. In patients with impaired
      renal function, post-contrast acute kidney injury (PC-AKI) has remained a significant
      concern. Modern retrospective studies have shown no association between worsened baseline
      renal function and IV-contrast CT. However, no randomised controlled trial has been done to
      conclude this. The INCARO (INtravenous Contrast computed tomography versus native computed
      tomography in patients with acute Abdomen and impaired Renal functiOn) trial is a
      multicentre, open-label, parallel group, superiority, individually randomised controlled
      trial comparing IV-contrast enhanced CT to native CT in patients with impaired renal
      function. Patients requiring emergency abdominal or body CT with eGFR 15-45 ml/min/1.73 m2
      are included in the study. The primary outcome is a composite outcome of all-cause mortality
      or renal replacement therapy within 90 days from CT.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">May 2033</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality or renal replacement therapy</measure>
    <time_frame>Within 90 days from CT</time_frame>
    <description>A composite outcome that combines all-cause mortality or renal replacement therapy (number of patients)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury (AKI) grade</measure>
    <time_frame>Within 72 hours after CT</time_frame>
    <description>The most severe acute kidney injury (AKI) grade defined by KDIGO classification on serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any organ failure</measure>
    <time_frame>48 hours after CT</time_frame>
    <description>Any organ failure defined by at least 2 SOFA (Sequential Organ Failure Assessment) points excluding central nervous system (number of patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive and hospital-free</measure>
    <time_frame>Within 90 days after CT</time_frame>
    <description>Alive and hospital-free (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from CT to definitive treatment</measure>
    <time_frame>During hospital stay estimated on average 7 days</time_frame>
    <description>Time from CT to definitive treatment (i.e. surgery, radiological intervention, endoscopy, medication)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>6 months from CT</time_frame>
    <description>All-cause mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>1 year from CT</time_frame>
    <description>All-cause mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>5 years from CT</time_frame>
    <description>All-cause mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>10 years from CT</time_frame>
    <description>All-cause mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal replacement therapy</measure>
    <time_frame>6 months from CT</time_frame>
    <description>Number of patients requiring renal replacement therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal replacement therapy</measure>
    <time_frame>1 year from CT</time_frame>
    <description>Number of patients requiring renal replacement therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal replacement therapy</measure>
    <time_frame>5 years from CT</time_frame>
    <description>Number of patients requiring renal replacement therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal replacement therapy</measure>
    <time_frame>10 years from CT</time_frame>
    <description>Number of patients requiring renal replacement therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal transplant</measure>
    <time_frame>6 months from CT</time_frame>
    <description>Number of patients undegoing renal transplant</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal transplant</measure>
    <time_frame>1 year from CT</time_frame>
    <description>Number of patients undegoing renal transplant</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal transplant</measure>
    <time_frame>5 years from CT</time_frame>
    <description>Number of patients undegoing renal transplant</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal transplant</measure>
    <time_frame>10 years from CT</time_frame>
    <description>Number of patients undegoing renal transplant</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">994</enrollment>
  <condition>Acute Abdomen</condition>
  <condition>Radiocontrast Nephropathy</condition>
  <arm_group>
    <arm_group_label>Abdominal or body CT with intravenous contrast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abdominal or body CT with intravenous contrast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abdominal or body CT without intravenous contrast (native CT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abdominal or body CT without intravenous contrast (native CT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Abdominal or body CT with intravenous contrast</intervention_name>
    <description>Abdominal or body CT with intravenous contrast</description>
    <arm_group_label>Abdominal or body CT with intravenous contrast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Abdominal or body CT without intravenous contrast (native CT)</intervention_name>
    <description>Abdominal or body CT without intravenous contrast (native CT)</description>
    <arm_group_label>Abdominal or body CT without intravenous contrast (native CT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients requiring emergency abdominal or body CT with eGFR 15-45 ml/min/1.73 m2

        Exclusion Criteria:

          -  Age less than 18 years

          -  eGFR less than 15 or more than 45 ml/min/1.73 m2

          -  Renal replacement therapy within 30 days prior enrolment

          -  CT with IV contrast less than 72 hours prior enrolment

          -  Suspicion of vascular occlusion, dissection or bleeding (i.e. need for IV-contrast)

          -  CT needed without IV-contrast to detect or rule out ureteral stone

          -  IV contrast allergy

          -  Inability to give written consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jorvi hospital, Helsinki University Hospital</name>
      <address>
        <city>Espoo</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meilahti hospital, Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Ville Sallinen, MD, PhD</last_name>
      <phone>+35894711</phone>
      <email>ville.sallinen@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyvinkää hospital</name>
      <address>
        <city>Hyvinkää</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Taina Nykänen, MD, PhD</last_name>
      <phone>+35894711</phone>
      <email>taina.nykanen@hus.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Ville Sallinen</investigator_full_name>
    <investigator_title>Adj. Prof., Consultant, Clinical researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Abdomen, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

